Arrowstreet Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

Arrowstreet Capital’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-238,503	Closed	-$2.49M	–	2197
2019 Q4	$2.49M	Buy	+238,503	New	+$1.73M	0.01%	1068
2013 Q4	–	Sell	-8,387	Closed	-$510K	–	1327
2013 Q3	$510K	Buy	+8,387	New	+$595K	﹤0.01%	792

Other funds holding CLVS

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Arrowstreet Capital's CLVS Position: Q1 2020 in Review

Arrowstreet Capital sold out of Clovis Oncology, Inc. (CLVS) in Q1 2020, closing a stake of 238,503 shares — an estimated $2.49M sold.

Arrowstreet Capital first reported a position in CLVS in Q3 2013 and held it in 2 quarters. The position peaked at $2.49M in Q4 2019. 154 funds tracked by Wall St. Rank hold CLVS as of Q1 2020.

Arrowstreet Capital reported no remaining Clovis Oncology, Inc. position as of Q1 2020 after selling out during the quarter.
Arrowstreet Capital sold 238,503 Clovis Oncology, Inc. shares in Q1 2020, an estimated $2.49M.
Arrowstreet Capital first reported a position in Clovis Oncology, Inc. in Q3 2013 and held it in 2 quarters.
Arrowstreet Capital's Clovis Oncology, Inc. position peaked at $2.49M in Q4 2019.
154 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2020.

Based on Arrowstreet Capital's 13F filing for Q1 2020, filed 15 May 2020.